SCHEMBL5107028

SCHEMBL5107028

CCOC(=O)c1c(C(O)c2c(C)nsc2C)sc2c1c(=O)n(C)c(=O)n2C(C)C

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.35
MAPT P10636 3/20 0.35
ALDH1A1 P00352 3/20 0.35
HPGD P15428 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
PKM P14618 1/20 0.35
HTT P42858 1/20 0.35
CCR6 P51684 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
SLC16A1 P53985 1/20 0.35
POLB P06746 1/20 0.34
GAA P10253 1/20 0.34
KDM4E B2RXH2 2/20 0.31
HSD17B10 Q99714 1/20 0.31
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5093395 0.80 SLC16A1 (0.42) LMNAMAPTALDH1A1HPGDSMN1; SMN2
SCHEMBL5100035 0.79 SLC16A1 (0.40) LMNAMAPTALDH1A1HPGDSMN1; SMN2
SCHEMBL5097003 0.76 SLC16A1 (0.37) LMNAMAPTALDH1A1HPGDPKM
SCHEMBL5097873 0.76 SLC16A1 (0.41) LMNAMAPTALDH1A1HPGDSMN1; SMN2
SCHEMBL5120600 0.75 GAA (0.36) LMNAMAPTALDH1A1HPGDSMN1; SMN2
SCHEMBL5096942 0.74 SLC16A1 (0.38) LMNAMAPTSMN1; SMN2HTTSLC16A1
SCHEMBL5093501 0.74 SLC16A1 (0.37) LMNAMAPTALDH1A1HPGDSMN1; SMN2
SCHEMBL5096911 0.70 SLC16A1 (0.44) SLC16A1
SCHEMBL5100042 0.69 SLC16A1 (0.43) LMNAMAPTALDH1A1HPGDSMN1; SMN2
SCHEMBL3829185 0.68 SLC16A1 (0.41) LMNAMAPTALDH1A1HPGDSLC16A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214579-A1 THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE ASTRAZENECA AB (SE) 2008-09-04 US disclosed
US-7384951-B2 Thienopyrimidinediones and their use in the modulation of autoimmune disease ASTRAZENECA AB (SE) 2008-06-10 US disclosed
EP-1587812-B1 THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE ASTRAZENECA AB (SE) 2006-08-09 EP disclosed
US-20060052400-A1 Thienopyriminediones and their use in the modulation of autoimmune disease ASTRAZENECA AB (SE) 2006-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214579-A1 THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE TPMT, TYMP, TYMS LMNA 4830/4885MAPT 3966/4885ALDH1A1 194/4885
US-20060052400-A1 Thienopyriminediones and their use in the modulation of autoimmune disease C5, HRH4, CYP2S1 LMNA 4869/4885MAPT 4836/4885ALDH1A1 1022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.